公开(公告)号：US20230027502A1

公开(公告)日：2023-01-26

申请号：US17777982

申请日：2020-05-29

申请人： PHARMA MAR, S.A.

发明人： Pilar Calvo ,  Carmen Kahatt ,  José María Fernandez ,  Maria Tobio ,  Salvador Fudio ,  Arturo Soto ,  Pilar Lardelli ,  Cristian Fernandez ,  Maria Del Mar Zarzuelo Alba ,  María de la Concepción Polanco Noain ,  Sonia Manzanaro López ,  Honorio Velasco

IPC分类号： A61K31/4995 ,  A61K31/573 ,  A61K9/00 ,  A61K31/4745 ,  A61K31/4738 ,  A61K38/19 ,  C07D519/00 ,  A61P35/00 ,  A61P11/00

摘要： Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

公开(公告)号：US20230012681A1

公开(公告)日：2023-01-19

申请号：US17288567

申请日：2019-10-25

申请人： PHARMA MAR, S.A.

发明人： Maria del Carmen Ceuvas Marchante ,  Andres M. Franoesch Solioso ,  Alfonso Latorre Lozano ,  Valentin Martinez Barrasa

IPC分类号： A61K47/68 ,  A61K31/4995 ,  A61P35/00

摘要： Drug conjugates having formula [D-(X)6-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to (X)b if any, or (AA)w if any, or to (T)g if any, or (L); that are useful in the treatment of cancer.

公开(公告)号：US11339180B2

公开(公告)日：2022-05-24

申请号：US17221445

申请日：2021-04-02

申请人： PHARMA MAR, S.A.

发明人： María del Carmen Cuevas Marchante ,  Andrés Francesch Solloso ,  Valentín Martínez Barrasa

IPC分类号： A61P35/00 ,  C07D515/22

摘要： A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.

公开(公告)号：US11332480B2

公开(公告)日：2022-05-17

申请号：US16608617

申请日：2018-04-27

申请人： Pharma Mar, S.A.

发明人： María del Carmen Cuevas Marchante ,  Andrés Francesch Solloso ,  Valentín Martínez Barrasa

IPC分类号： C07D515/22 ,  A61P35/00

摘要： A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.

公开(公告)号：US20210317490A1

公开(公告)日：2021-10-14

申请号：US16494720

申请日：2018-03-16

申请人： Pharma Mar, S.A.

发明人： Librada María CAÑEDO HERNÁNDEZ ,  Fernando DE LA CALLE VERDÚ ,  María Pilar RODRÍGUEZ RAMOS ,  María del Carmen SCHLEISSNER SÁNCHEZ ,  Paz ZÚÑIGA GIRÓN

IPC分类号： C12P17/06 ,  C12N1/20 ,  C07D407/12

摘要： Anticancer compounds of general formula I wherein R1 to R4 take various meanings, for use in the treatment of cancer. A novel Labrenzia sp. strain named PHM005 with Accession Deposit Number CECT-9225, a method of producing compounds of the invention and analogues thereof by using the PHM005 strain and the Lab gene cluster codifying the biosynthesis of pederin-like and onnamide-like compounds are also provided.

公开(公告)号：US10538535B2

公开(公告)日：2020-01-21

申请号：US15964381

申请日：2018-04-27

申请人： Pharma Mar, S.A.

发明人： María del Carmen Cuevas Marchante ,  Andrés Francesch Solloso ,  Valentín Martínez Barrasa

IPC分类号： C07D515/22 ,  A61P35/00

摘要： A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.

公开(公告)号：US20180008602A1

公开(公告)日：2018-01-11

申请号：US15711478

申请日：2017-09-21

申请人： PHARMA MAR, S.A.

发明人： Victoria MONEO OCAÑA ,  Gema SANTAMARÍA NÚÑEZ ,  Luis Francisco GARCÍA FERNÁNDEZ ,  Carlos María GALMARINI ,  María José GUILLÉN NAVARRO ,  Pablo Manuel AVILÉS MARÍN

IPC分类号： A61K31/4995 ,  A61K38/15 ,  A61K33/24 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/55 ,  A61K31/337 ,  A61K31/519 ,  A61K31/513 ,  A61K31/4375 ,  A61K31/4188 ,  A61K31/4164 ,  A61K45/06 ,  A61K31/69

摘要： The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.

公开(公告)号：US09827257B2

公开(公告)日：2017-11-28

申请号：US14824699

申请日：2015-08-12

申请人： PHARMA MAR, S.A.

发明人： Alberto Rodriquez Vicente ,  Maria Garranzo Garcia-Ibarrola ,  Carmen Murcia Perez ,  Francisco Sanchez Sancho ,  Maria del Carmen Cuevas Marchante ,  Cristina Mateo Urbano ,  Isabel Digon Juarez

IPC分类号： A61K31/695 ,  A61K31/351 ,  A61K31/366 ,  C07F7/18 ,  C07D309/10 ,  C07D309/30 ,  C07D309/32

CPC分类号： A61K31/695 ,  A61K31/351 ,  A61K31/366 ,  C07D309/10 ,  C07D309/30 ,  C07D309/32 ,  C07F7/1804 ,  Y02P20/55

摘要： A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.

公开(公告)号：US20180312529A1

公开(公告)日：2018-11-01

申请号：US15964381

申请日：2018-04-27

申请人： Pharma Mar, S.A.

发明人： María del Carmen Cuevas Marchante ,  Andrés Francesch Solloso ,  Valentín Martínez Barrasa

IPC分类号： C07D515/22 ,  A61P35/00

摘要： A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.

公开(公告)号：US20010039041A1

公开(公告)日：2001-11-08

申请号：US09756244

申请日：2001-01-08

申请人： Pharma Mar, S.a.

发明人： Glynn T. Faircloth JR. ,  Francisco Romero Millan ,  Librada Maria Canedo Fernandez ,  Cristina Accbal Sarabia

IPC分类号： A61K031/335 ,  C12P001/04 ,  C12P017/00 ,  A01N043/32

CPC分类号： C12P17/00 ,  A61K31/341 ,  A61K31/453 ,  A61K45/06 ,  C12P1/04 ,  A61K2300/00

摘要： The active component of the pharmaceutical composition of the present invention is a compound which has been isolated from the controlled aerobic fermentation of a marine microorganism, Agrobacterium sp. PH-103. The pharmaceutical compositions of the present invention, useful for post surgical graft tolerance, are thus directed to compositions comprising a pharmaceutically acceptable carrier, diluent or excipient, and an effective amount of the compound having the formula: 1 This compound, known as Sesbanimide, is an alkaloid that has been previously been isolated from seeds and reported to be useful as an antitumor drug. Prior to the present invention however, this compound had not been isolated from any fermentation broth nor had it been determined to have immunomodulatory activity.

摘要翻译： 本发明的药物组合物的活性组分是从海洋微生物农杆菌属的受控好氧发酵中分离的化合物。 PH-103。 因此，可用于手术后移植物耐受性的本发明的药物组合物涉及包含药学上可接受的载体，稀释剂或赋形剂和有效量的具有下式的化合物的组合物：称为Sesbanimide的该化合物是 生物碱以前已经从种子中分离出来，据报道可用作抗肿瘤药物。 然而，在本发明之前，该化合物没有从任何发酵液中分离，也没有确定具有免疫调节活性。